Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
LIVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$32.48 - $57.35
Previous CloseN/A
Volume66.13K
Average Volume (3M)748.33K
Market Cap
$2.93B
Enterprise Value$2.35B
Total Cash (Recent Filing)$593.64M
Total Debt (Recent Filing)$473.40M
Price to Earnings (P/E)30.6
Beta0.89
Next Earnings
Oct 29, 2025EPS Estimate
0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.05
Shares Outstanding54,601,074
10 Day Avg. Volume960,197
30 Day Avg. Volume748,329
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.60
Enterprise Value/Ebitda-32.14
Forecast
1Y Price Target
$74.20Price Target Upside38.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLIVN's second-quarter revenue and earnings per share exceeded expectations, showcasing strong financial performance.
Market ExpansionLivaNova received approval for the Essenz product in China, its second-largest market, which marks a significant expansion opportunity.
Product DevelopmentThe commitment to expanding oxygenator capacity is expected to enhance supply capabilities and support growth in the cardiopulmonary segment.
Bears Say
Epilepsy Business ChallengesUS Epilepsy business faced procedure deferrals due to a field service notification, impacting revenue and financial performance.
Product Safety And DesignA field safety notice required a design change for a small percentage of SenTiva generators, affecting current and past units.
Valuation ConcernsA recent downgrade to Peer Perform after a long period with a positive rating reflects concerns about the stock's valuation and potential risks.
LivaNova News
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $32.48 and its highest was $57.35 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $2.93B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Oct 29, 2025 which is in 71 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Aug 06, 2025. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.867 by $0.183.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 0.93.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,601,074 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $1.05 in its last earnings report, beating expectations of $0.867. Following the earnings report the stock price went up 11.148%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
LivaNova Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.20 (38.12% Upside)
$74.20 (38.12% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 436.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.07%
12-Months-Change
Fundamentals
Return on Equity
-17.87%
Trailing 12-Months
Asset Growth
2.18%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova (LIVN) is a global medical technology company focused on developing innovative therapies for patients suffering from severe neurological and cardiovascular conditions. The company operates primarily in two sectors: cardiovascular and neuromodulation. LivaNova's core products include advanced cardiac surgery devices, neuromodulation devices for epilepsy treatment, and various other therapeutic solutions aimed at improving patient outcomes and enhancing surgical procedures.
LIVN Company Deck
LIVN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a robust performance with significant revenue growth and clinical progress, particularly in epilepsy and cardiopulmonary segments. However, supply chain challenges and some transitional issues in neuromodulation pose risks. Overall, the sentiment is positive given the strong financial performance and raised guidance.View all LIVN earnings summariesLIVN Stock 12 Month Forecast
Average Price Target
$74.20
▲(38.12% Upside)
Technical Analysis
Integra Lifesciences
―
Ufp Technologies
―
TransMedics Group
―
Cytek Biosciences
―
PROCEPT BioRobotics
―
Ownership Overview
0.28% Insiders
31.65% Mutual Funds
29.72% Other Institutional Investors
18.66% Public Companies and
Individual Investors